Last reviewed · How we verify
NCT06092970
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
trial testing RBT-1 in Post-Operative Complications in Cardiac Surgery in 379 participants. Participants enrolled and being followed up; not accepting new ones.
30 June 2026
Quick facts
| Lead sponsor | Renibus Therapeutics, Inc. |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 379 |
| Start date | 16 October 2023 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 39 locations across Canada, United States |
Drugs / interventions tested
- RBT-1 — full drug profile →
- Placebo
Conditions studied
- Post-Operative Complications in Cardiac Surgery — all drugs for Post-Operative Complications in Cardiac Surgery →
Sponsor
Renibus Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Post-Operative Complications in Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: * Patient reported outcomes (PRO), using the EQ-5D questionnaire * Clinical outcomes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06092970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RBT-1
Trials testing the same drug.
- NCT06021457 — Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery · Phase 3 · completed
- NCT03893799 — A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease · Phase 1 · completed
Other Renibus Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07009340 — Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valv · active not recruiting
- NCT06021457 — Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery · Phase 3 · completed
- NCT04564833 — Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery · Phase 2 · completed
- NCT04364763 — A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) · Phase 2 · terminated
- NCT03893799 — A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06092970 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renibus Therapeutics, Inc.
- Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06092970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing